| 2023-12-07 | -1.66 % |
|
| 2023-12-06 | -0.56 % |
|
| 2023-12-05 | +1.11 % |
|
| 2023-12-04 | +1.55 % |
|
| 2023-11-30 | +1.33 % |
|
| 2023-11-29 | +0.95 % |
|
| 2023-11-28 | -1.23 % |
|
| 2023-11-24 | +0.19 % |
|
| 2023-11-22 | -0.52 % |
|
| 2023-11-21 | -0.46 % |
|
| 2023-11-20 | +0.91 % |
|
| 2023-11-17 | -0.24 % |
|
| 2023-11-15 | -0.8 % |
|
| 2023-11-14 | -0.29 % |
|
| 2023-11-13 | +1.07 % |
|
| 2023-11-10 | -0.97 % |
|
| 2023-11-08 | +0.38 % |
|
| 2023-11-07 | -0.33 % |
|
| 2023-11-06 | +0.93 % |
|
| 2023-11-03 | +0.52 % |
|
| 2023-11-02 | |
- Moderna Inc. reported a wider loss than expected in the third quarter and lowered its full-year sales outlook, leading to a 4.8% decline in its stock price; the loss was driven by non-cash charges related to resizing and tax valuation allowances, including write-downs on excess and obsolete COVID products.
- Merck & Co. (MRK) stock went down by 0.0% last night, and the reason for the decrease is not provided in the article.
- Merck & Co. (MRK) stock went down by 0.0% last night, likely due to the company's financial results for the third quarter of 2023, which showed a decrease in revenue and net income compared to the same period in 2022. Factors contributing to the decline include decreased sales in the Women's Health segment due to generic competition for NuvaRing, as well as unfavorable discount rates and a change in the go-to-market model for Nexplanon. The Biosimilars segment saw growth, driven by strong demand for Renflexis and Ontruzant. The Established Brands segment also experienced growth, despite the impact of Volume Based Procurement initiatives in China. The company has updated its full year 2023 financial guidance, narrowing and lowering the revenue range and adjusting the EBITDA margin range to reflect current foreign currency exchange rates, changes to the go-to-market model for Nexplanon, and macroeconomic factors in China.
|
| 2023-11-01 | +0.15 % |
|
| 2023-10-31 | +0.02 % |
|
| 2023-10-27 | -2.59 % |
|
| 2023-10-26 | +1.85 % |
|
| 2023-10-23 | +0.66 % |
|
| 2023-10-20 | +2.23 % |
|
| 2023-10-19 | -1.53 % |
|
| 2023-10-17 | +0.03 % |
|
| 2023-10-16 | +0.12 % |
|
| 2023-10-11 | -0.14 % |
|
| 2023-10-10 | -0.85 % |
|
| 2023-10-05 | +1.4 % |
|
| 2023-10-03 | -0.76 % |
|
| 2023-09-29 | -1.29 % |
|
| 2023-09-28 | +0.35 % |
|
| 2023-09-27 | -1.38 % |
|
| 2023-09-26 | -0.43 % |
|
| 2023-09-25 | -0.47 % |
|
| 2023-09-22 | -0.37 % |
|
| 2023-09-20 | -0.05 % |
|
| 2023-09-19 | -0.43 % |
|
| 2023-09-18 | +0.28 % |
|
| 2023-09-15 | -0.67 % |
|
| 2023-09-14 | +0.4 % |
|
| 2023-09-13 | -1.11 % |
|
| 2023-09-12 | +0.39 % |
|
| 2023-09-11 | -0.41 % |
|
| 2023-09-07 | +1.36 % |
|
| 2023-09-06 | -0.95 % |
|
| 2023-09-05 | -2.12 % |
|
| 2023-08-31 | -1.12 % |
|
| 2023-08-30 | +0.2 % |
|
| 2023-08-29 | +0.97 % |
|
| 2023-08-28 | -1.16 % |
|
| 2023-08-25 | +0.69 % |
|
| 2023-08-24 | -1.66 % |
|
| 2023-08-23 | +3.8 % |
|
| 2023-08-22 | -2.2 % |
|
| 2023-08-21 | +0.4 % |
|
| 2023-08-18 | +0.26 % |
|
| 2023-08-17 | +0.17 % |
|
| 2023-08-15 | -0.23 % |
|
| 2023-08-14 | +1.37 % |
|
| 2023-08-11 | +1.77 % |
|
| 2023-08-10 | -0.5 % |
|
| 2023-08-08 | +0.3 % |
|
| 2023-08-07 | +1.04 % |
|
| 2023-08-01 | -1.28 % |
|
| 2023-07-31 | +0.29 % |
|
| 2023-07-28 | +1.02 % |
|
| 2023-07-26 | -0.36 % |
|
| 2023-07-25 | -1.16 % |
|
| 2023-07-21 | +1.78 % |
|
| 2023-07-19 | |
|
| 2023-07-13 | -1.07 % |
|
| 2023-07-12 | -1.13 % |
|
| 2023-07-11 | -1.15 % |
|
| 2023-07-05 | -0.55 % |
|
| 2023-06-29 | +0.98 % |
|
| 2023-06-14 | -1.21 % |
|
| 2023-06-13 | +0.12 % |
|
| 2023-06-09 | +0.35 % |
|
| 2023-06-08 | +1.57 % |
- Healthcare stocks have outperformed the broader market in recent years due to their defensive nature and adaptability to changes brought about by the COVID-19 pandemic, which has attracted billionaire investors to companies such as Abbott Laboratories, Johnson & Johnson, and McKesson Corporation. Additionally, advancements in medical technology and telehealth have contributed to the long-term growth potential of the healthcare sector, leading to strong cash positions and dividend growth for companies like Humana Inc. and Bio-Rad Laboratories Inc., while DexCom, Inc. has seen revenue growth from manufacturing glucose monitoring systems for diabetes management.
- The article provided does not mention anything about Merck & Co. (MRK) stock going up, therefore it cannot be answered why it has gone up. The article pertains to the announcement of the annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. on July 18, 2023, and the proposals and recommendations for shareholders to vote on.
- Merck & Co's stock went up by 1.57% after US FDA accepted its application for expanded use of cancer drug Keytruda in combination with chemotherapy for patients with locally advanced unresectable or metastatic biliary tract cancer, which is based on positive Phase 3 study results showing a statistically significant improvement in overall survival.
|
